Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

1061P - Safety of cemiplimab for advanced cutaneous squamous cell carcinoma: The Spanish named patient programme

Date

16 Sep 2021

Session

ePoster Display

Topics

Tumour Site

Skin Cancers

Presenters

Almudena Garcia Castano

Citation

Annals of Oncology (2021) 32 (suppl_5): S867-S905. 10.1016/annonc/annonc706

Authors

A. Garcia Castano1, E. Muñoz Couselo2, A. Soria3, J. Lavernia4, O. Sanmartin5, J. Cañueto6, P. Ayala de Miguel7, S. Beá Ardébol8, L. Bellido Hernández9, R. Fernández-de-Misa Cabrera10, A.J. Cunquero-Tomás11, L. Fernández Franco12, A. Férnandez-Freire Leal13, K. Mujika Eizmendi14, C. Ortiz15, P. Redondo16, I. Romero17, M. Serrano Fernández1, J. Medina Martínez12

Author affiliations

  • 1 Medical Oncology, Hospital Universitario Marqués de Valdecilla, 39008 - Santander/ES
  • 2 Medical Oncology, Hospital Vall d'Hebron, 08035 - Barcelona/ES
  • 3 Medical Oncology, Hospital Universitario Ramón y Cajal, 28034 - Madrid/ES
  • 4 Medical Oncology, Fundación Instituto Valenciano de Oncologia (IVO), 46009 - Valencia/ES
  • 5 Dermatology, Fundación Instituto Valenciano de Oncología (IVO), 46009 - Valencia/ES
  • 6 Dermatology, Complejo Asistencial Universitario de Salamanca, 37007 - Salamanca/ES
  • 7 Medical Oncology, Complejo Hospitalario Universitario de Cáceres, 10002 - Cáceres/ES
  • 8 Dermatology, Hospital Universitario Ramón y Cajal, 28034 - Madrid/ES
  • 9 Medical Oncology, Complejo Asistencial Universitario de Salamanca, 37007 - Salamanca/ES
  • 10 Dermatology, Hospital Universitario Nuestra Señora de Candelaria, 38010 - Santa Cruz de Tenerife/ES
  • 11 Medical Oncology, Consorcio Hospital General Universitario de Valencia, 46014 - Valencia/ES
  • 12 Medical Oncology, Hospital Virgen de la Salud, 45004 - Toledo/ES
  • 13 Medical Oncology, Hospital Torrecardenas, 04009 - Almería/ES
  • 14 Medical Oncology, UGC de Oncología de Gipuzkoa OSI Donostialdea - Onkologikoa, 20014 - Donostia - San Sebastián/ES
  • 15 Medical Oncology, Vall d’Hebron Instituto de Oncología (VHIO), 08035 - Barcelona/ES
  • 16 Dermatology, Clínica Universidad de Navarra, 31008 - Pamplona/ES
  • 17 Medical Oncology, Instituto Valenciano de Oncología (IVO), 46008 - Valencia/ES
More

Resources

Abstract 1061P

Background

Cemiplimab is a programmed cell death receptor-1 inhibitor with antitumour activity for cutaneous squamous cell carcinoma (CSCC) and acceptable safety proved in its pivotal trial. We provide the first data on cemiplimab safety in daily practice from the named patient programme (NPP) for advanced CSCC in Spain.

Methods

This cemiplimab NPP was performed from March 2019 to March 2020. It included patients aged ≥18 years with advanced CSCC and ineligible for surgery, radiation therapy or clinical trials. The cemiplimab safety was assessed according to treatment-emergent adverse events (TEAEs) reported until March 2021.

Results

140 patients were included (median age [interquartile range, IQR] 77.0 [65.0-84.0] years; age ≥80 38%; men 71.7%; ≥1 comorbidity 83%; ECOG 0-1 86.3%; locally advanced CSCC 60.7%; cemiplimab as first-line therapy 67.7%). Cemiplimab was received for a median (IQR) of 8.0 (3.0-14.0) cycles. Fifty-eight (41.4%) patients showed ≥1 of the 163 TEAEs reported, which most frequently included diarrhoea n=7, asthenia n=6, constipation n=4 and abdominal pain n=4. Fourteen (8.6%) were immune-mediated, mainly bronchitis n=2, pneumonitis n=2 and hepatitis n=2. Seventy-eight (47.9%) TEAEs were grade ≥3, most frequently pneumonia n=3, COVID-19 n=3, general physical health deterioration n=2, pyrexia n=2, renal transplant failure n=2, sepsis n=2, acute kidney injury n=2 and respiratory failure n=2. Twenty-one (12.9%) were treatment-related (TREAEs): 11 (6.7%) were grade 1-2 (diarrhoea n=3 and asthenia, hepatotoxicity, malnutrition, odynophagia, polymyalgia rheumatica, pneumonitis, pruritus, and skin toxicity), 9 (5.5%) grade 3 (acute kidney injury, adrenal insufficiency, abdominal pain, blood creatinine increased, dysphagia, haematuria, immune-mediated enterocolitis, panniculitis, surgical wound infection) and 1 (0.6%) unknown grade. Cemiplimab was withdrawn due to TREAEs in only 5 (3.6%) patients. The TEAE outcome was fatal in 29 (17.8%); none related to cemiplimab.

Conclusions

This NPP supports the real-life safety of cemiplimab for CSCC, showing an acceptable safety profile consistent with previous reports.

Clinical trial identification

Editorial acknowledgement

Editorial assistance was provided by Esther Álvarez-García at Dynamic Science S.L., funded by Sanofi.

Legal entity responsible for the study

Sanofi.

Funding

Sanofi.

Disclosure

E. Muñoz Couselo: Financial Interests, Personal, Advisory Board: Amgen; Financial Interests, Personal, Advisory Board: Bristol-Myers Squibb; Financial Interests, Personal, Advisory Board: Merck Sharp & Dohme; Financial Interests, Personal, Advisory Board: Novartis; Financial Interests, Personal, Advisory Board: Pierre Fabre; Financial Interests, Personal, Advisory Board: Roche; Financial Interests, Personal, Advisory Board: Sanofi; Financial Interests, Personal, Other, Honoraria: Amgen; Financial Interests, Personal, Other, Honoraria: Bristol-Myers Squibb; Financial Interests, Personal, Other, Honoraria: Merck Sharp & Dohme; Financial Interests, Personal, Other, Honoraria: Novartis; Financial Interests, Personal, Other, Honoraria: Pierre Fabre; Financial Interests, Personal, Other, Honoraria: Roche; Financial Interests, Personal, Principal Investigator: Amgen; Financial Interests, Personal, Principal Investigator: Bristol-Myers Squibb; Financial Interests, Personal, Principal Investigator: GlaxoSmithKline; Financial Interests, Personal, Principal Investigator: Merck Sharp & Dohme; Financial Interests, Personal, Principal Investigator: Novartis; Financial Interests, Personal, Principal Investigator: Pierre Fabre; Financial Interests, Personal, Principal Investigator: Roche; Financial Interests, Personal, Principal Investigator: Sanofi. A. Soria: Financial Interests, Personal, Invited Speaker: Novartis; Financial Interests, Personal, Invited Speaker: Sanofi Aventis; Financial Interests, Personal, Invited Speaker: Roche Pharma; Financial Interests, Personal, Invited Speaker: Merck Serono; Financial Interests, Personal, Invited Speaker: Merck Sharp & Dohme; Financial Interests, Personal, Invited Speaker: Bristol-Myers Squibb; Financial Interests, Personal, Invited Speaker: Pierre Fabre; Financial Interests, Personal, Advisory Board: Novartis; Financial Interests, Personal, Advisory Board: Sanofi Aventis; Financial Interests, Personal, Advisory Board: Roche Pharma; Financial Interests, Personal, Advisory Board: Merck Serono; Financial Interests, Personal, Advisory Board: Merck Sharp & Dohme; Financial Interests, Personal, Advisory Board: Bristol-Myers Squibb; Financial Interests, Personal, Advisory Board: Pierre Fabre; Financial Interests, Personal, Principal Investigator: Novartis; Financial Interests, Personal, Principal Investigator: Sanofi Aventis; Financial Interests, Personal, Principal Investigator: Roche Pharma; Financial Interests, Personal, Principal Investigator: Merck Serono; Financial Interests, Personal, Principal Investigator: Merck Sharp & Dohme; Financial Interests, Personal, Principal Investigator: Bristol-Myers Squibb; Financial Interests, Personal, Principal Investigator: Pierre Fabre. O. Sanmartin: Financial Interests, Personal, Invited Speaker: Sanofi Genzyme; Financial Interests, Personal, Advisory Board: Sanofi Genzyme; Financial Interests, Personal, Officer: Sanofi Genzyme; Financial Interests, Personal, Principal Investigator: Sanofi Genzyme; Financial Interests, Personal, Invited Speaker: Roche Pharma; Financial Interests, Personal, Advisory Board: Roche Pharma; Financial Interests, Personal, Officer: Roche Pharma; Financial Interests, Personal, Principal Investigator: Roche Pharma. J. Cañueto: Financial Interests, Personal, Invited Speaker: Hoffman-La Roche; Financial Interests, Personal, Invited Speaker: Sanofi-Genzyme; Financial Interests, Personal, Invited Speaker: AbbVie; Financial Interests, Personal, Invited Speaker: LeoPharma; Financial Interests, Personal, Other, Consultancy: Sanofi-Genzyme; Financial Interests, Personal, Other, Consultancy: InflaRx; Financial Interests, Personal, Other, Consultancy: Almirall. S. Beá Ardébol: Financial Interests, Personal, Invited Speaker: Meda; Financial Interests, Personal, Advisory Board: Sanofi; Financial Interests, Personal, Advisory Board: SunPharma; Financial Interests, Personal, Other, Trial subinvestigator: Sanofi Aventis; Financial Interests, Personal, Other, Trial subinvestigator: SunPharma; Financial Interests, Personal, Other, Trial subinvestigator: PellePharma. R. Fernández-de-Misa Cabrera: Financial Interests, Personal, Advisory Board: Sanofi. A.J. Cunquero-Tomás: Financial Interests, Personal, Invited Speaker: BMS; Financial Interests, Personal, Invited Speaker: Pierre-Fabre; Financial Interests, Personal, Writing Engagements: Sanofi; Financial Interests, Personal, Other, 2021 EADO/WMC Congress inscription fee: Sanofi. L. Fernández Franco: Non-Financial Interests, Personal, Invited Speaker: Merck; Non-Financial Interests, Personal, Invited Speaker: Sanofi; Non-Financial Interests, Personal, Invited Speaker: Servier. I. Romero: Financial Interests, Personal, Invited Speaker: Pharmamar; Financial Interests, Personal, Invited Speaker: Roche; Financial Interests, Personal, Invited Speaker: GSK; Financial Interests, Personal, Invited Speaker: Clovis; Financial Interests, Personal, Invited Speaker: AstraZeneca; Financial Interests, Personal, Advisory Board: Pharmamar; Financial Interests, Personal, Advisory Board: Roche; Financial Interests, Personal, Advisory Board: GSK; Financial Interests, Personal, Advisory Board: Clovis; Financial Interests, Personal, Advisory Board: AstraZeneca. J. Medina Martínez: Non-Financial Interests, Personal, Invited Speaker: Roche; Non-Financial Interests, Personal, Speaker’s Bureau: Roche; Non-Financial Interests, Personal, Advisory Board: Roche; Non-Financial Interests, Personal, Invited Speaker: Novartis; Non-Financial Interests, Personal, Speaker’s Bureau: Novartis; Non-Financial Interests, Personal, Advisory Board: Novartis; Non-Financial Interests, Personal, Invited Speaker: BMS; Non-Financial Interests, Personal, Speaker’s Bureau: BMS; Non-Financial Interests, Personal, Advisory Board: BMS; Non-Financial Interests, Personal, Invited Speaker: MSD; Non-Financial Interests, Personal, Speaker’s Bureau: MSD; Non-Financial Interests, Personal, Invited Speaker: Pierre Fabre; Non-Financial Interests, Personal, Speaker’s Bureau: Pierre Fabre; Non-Financial Interests, Personal, Advisory Board: Pierre Fabre; Non-Financial Interests, Personal, Invited Speaker: Merk; Non-Financial Interests, Personal, Speaker’s Bureau: Merk; Non-Financial Interests, Personal, Invited Speaker: Sanofi; Non-Financial Interests, Personal, Speaker’s Bureau: Sanofi; Non-Financial Interests, Personal, Advisory Board: Sanofi; Non-Financial Interests, Personal, Invited Speaker: Servier. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.